Latest News and Press Releases

NEWARK, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) announced today the presentation of ten abstracts at PAINWeek® 2016, the nation's largest annual meeting for frontline...

- Second Quarter Revenues of $117 million, 23% over 2Q 2015 -- NUCYNTA® Franchise Second Quarter 2016 Record Net Sales of $72 million, 27% over 2Q 2015 -- Conference Call Scheduled for Today at 4:30...

NEWARK, Calif., July 27, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release second quarter fiscal year 2016 financial results after the close of market,...

NEWARK, Calif., July 06, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced its participation at Cantor Fitzgerald’s 2nd Annual Healthcare Conference in New York, New York. ...

NEWARK, Calif., June 23, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that, in response to a second record date request by Starboard Value LP, it has set a record date of...

NEWARK, Calif., June 14, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the JMP Securities 2016 Life Sciences Conference in New York, New York....

NEWARK, Calif., May 26, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) ("Depomed" or the "Company") today issued the following statement in response to Starboard Value LP’s (“Starboard”)...

NEWARK, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that clinical data from Phase IIb trials of cebranopadol in chronic lower back pain (cLBP) and diabetic...

NEWARK, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that on May 18, 2016, Judge Claire C. Cecchi of the United States District Court for the District...

NEWARK, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that clinical data from two Phase IIb trials as well as human abuse potential and respiratory depression...